2023 Conference DAY 2
Download your copy of the 2023 full event guide for a comprehensive view of both conference days.
8:00 am Morning Networking
8:50 am Chair’s Opening Remarks
Accelerating Clinical Adoption of Liquid Biopsies For Earlier Patient Access
9:00 am Patient Access to Liquid Biopsy Quality Testing
Synopsis
- Painting a picture of the patients understanding of liquid biopsy
- Developing a robust infrastructure; where to get tested and who pays for it?
- Interpreting tests to ensure actionability
9:30 am Panel Discussion: Driving Widespread Adoption of Reproducible, Innovative & Clinically Validated LBx Tests to Improve Patient Access through Increased Reimbursements
Synopsis
- What are the challenges faced in obtaining reimbursement for LBx tests?
- How to advise recommendations to improve reimbursement policies for LBx tests used in surveillance?
- What role does standardization, enhanced evidence generation, and ongoing communication/collaboration between stakeholders play in achieving reimbursements?
10:00 am Morning Networking Break
Utilizing ctDNA, cfRNA, & cfDNA for Tumor Profiling to Predict Disease Progression & Identify High-Risk Patients
11:00 am Background Variability of ctDNA Levels in Plasma of Patients with Advanced Lung Cancer in the Absence of Treatment
Synopsis
- Quantifying changes in circulating tumor DNA (ctDNA) can rapidly identify patients responding to therapy
- Accurate quantification of ctDNA levels is required and it’s important to understand biological and technical variabilities in ctDNA measurements
- The results of our analysis of technical and biological variability of ctDNA levels in pre-treatment samples from patients with advanced EGFRm NSCLC, highlighting the importance of biological variability and the stringent molecular response definition
11:30 am New Paradigm in Liquid Biopsy: Combined Cell-Free RNA (cfRNA) & DNA (cfDNA)
Synopsis
- Increasing sensitivity and specific of liquid bx by adding cfRNA testing to cfDNA testing
- cfRNA provides a spectrum of biomarkers that can be used for classification of the tumor, predicting prognosis, and evaluating the host immune response
- Reliable detection of fusion genes when cfRNA is used even when the partner gene is not known
12:00 pm ctDNA in Metastatic Settings to Assess Progression & Molecular Responses for the Identification of High-Risk Patients
Synopsis
- How ctDNA is used for progression and identifying high risk patients that will progress further than others in the metastatic setting?
- How to implement ctDNA surrogate biomarkers in clinical trials?
- What is the best assay to assess the molecular response in metastatic setting?
- How to harmonize the generation of data across the industry to do meta-data analysis for on-going clinical trials and learn how to use ctDNA?
12:30 pm Lunch & Networking Break
Implementing Post-Diagnosis Longitudinal Monitoring to Evaluate Tumor Progression & Resistance for Robust Treatment Management
Chair:
1:30 pm Uncovering the Clinical Utility of Chromosomal Instability from cfDNA Demonstrating Clinical Impact of Longitudinal Monitoring Pre- & Post-Surgery
Synopsis
- Using novel bioinformatic techniques to identify and validate the presence of chromosomal instability in cfDNA as a potential biomarker for cancer detection.
- Longitudinal monitoring of cfDNA chromosomal instability among pre- and post-surgery samples.
- Exploring the clinical applications of cfDNA chromosomal instability
2:00 pm Unraveling the Implications of ctDNA As a Biomarker Using Tumor-Informed MRD for Solid Tumors
Synopsis
• ctDNA is a good biomarker in MRD determination, the prognosis value of using ctDNA to determine MRD status in solid tumor had been demostrated in many clinical study.
• The sensitivity of the MRD test plays a crucial role in detecting ctDNA in patients due to the extremely low abundance of ctDNA in blood.
• brPROPHET adopts a tumor-informed personalized panel approach on MRD assessment with a limit of detection of 40 ppm, which its capabilities of prognosis prediction and monitoring therapeutic response have been shown in clinical studies on different cancer types
2:30 pm Using ctDNA to Guide Clinical Decision Making in Phase I Oncology Trials
Synopsis
- ctDNA can be more useful than tumor tissue in identification or screening patients
- ctDNA can be a PD biomarker as well early indicator of clinical efficacy
- Longitudinal monitoring emerging tumor gene alterations in ctDNA can help understand resistance mechanisms and guide patient management
3:00 pm Liquid Biopsy in Post Diagnosis for Early Cancer Monitoring
Synopsis
Details to be revealed
3:30 pm Afternoon Networking Break
Harnessing Microfluidic, Methylation & Fragmentomic Strategies to Characterize Targets for Earlier Detection
Chair:
4:00 pm LBx-Based Early Detection of Heterotopic Ossification
Synopsis
- There is an urgent need for screening and diagnostic technologies for trauma-associated conditions
- High-throughput microfluidic technology enables the isolation of rare cells from blood samples as LBx
- Rare circulating cells enable early detection of trauma-induced or genetic forms of heterotopic ossification
4:30 pm TM4SF1: An Attractive Target for Early Detection of Solid Tumors
Synopsis
- What are the challenges associated with the low number of CTCs?
- Why is it important to identify the CTCs before they progress into a tumor in early detection?
- How to use Affymetrix to identify novel targets?
- How to characterize functions of ADCs as target for liquid biopsies?
- How to use Affymetrix to identify novel targets?
5:00 pm Strategies to Boost ctDNA MRD Sensitivity
Synopsis
- Clinical data regarding sensitivity and specificity in patients
- Novel strategies to boost sensitivity outside of blood plasma (e.g. proximal biofluids)
- Looking at cfDNA such as methylation and fragmentomics to increase sensitivity